Distribution agreement with Gorea Plus

mir|detect concludes distribution agreement with Gorea Plus for Croatia

Bremerhaven, 08 July 2025 - The mir|detect GmbHa company based in Bremerhaven and specialising in molecular diagnostics, has acquired a Distribution agreement with Gorea Plus d.o.o. was concluded. The partnership means that the CE-IVD-certified M371-Test of mir|detect in future also in Croatia be available.

With this co-operation mir|detect continues its European expansion and strengthens the availability of modern miRNA-based diagnostics in Croatia. Gorea Plus, based in Novigrad, is an established distributor of medical and diagnostic products and has many years of experience in the distribution of high-quality laboratory solutions. The company will be responsible for the marketing, distribution and technical support of the M371-Test in the Croatian market.

The M371-Test is a minimally invasive blood test for the diagnosis and aftercare of testicular cancer. It uses the biomarker miR-371a-3pwhich has a significantly higher sensitivity and specificity than conventional serum tumour markers. With a Sensitivity of over 90 % and one Specificity of 100 % the test provides reliable results for the early detection of testicular germ cell tumours (TGCTs). This makes a significant contribution to avoiding overtreatment and reducing the use of stressful imaging procedures.

"With Gorea Plus, we have gained a strong partner who knows the diagnostic needs of the Croatian market very well," says Dr Nina Winter, CEO of mir|detect. "Together, we want to significantly improve access to precise, standardised and IVDR-compliant molecular diagnostics for testicular cancer."

The co-operation with Gorea Plus marks another important step in the European growth strategy of mir|detect. Following the successful introduction of the M371-Test in several countries, the company is expanding its presence in south-east Europe. The aim is to provide doctors and laboratories in the region with access to a reliable, validated and CE-IVD-certified test solution.

Further information can be found in our Sales partner area or under www.gorea-plus.hr to find.

About mir|detect

The mir|detect GmbH based in Bremerhaven, Germany, develops and produces nucleic acid-based in-vitro diagnostics for the early detection and aftercare of cancer. The CE-IVD-certified flagship product, the M371-Testenables the high-precision diagnosis and monitoring of testicular germ cell tumours. Based on the patented and innovative panta|Q® Technology mir|detect is working on a new generation of liquid biopsy tests.

Contact:
mir|detect GmbH
Fischkai 1 - 27572 Bremerhaven
E-Mail: info@mirdetect.deWeb: www.mirdetect.de

Copyright by me|detect & 21HAVN